Skip to main content
Beckman Coulter secures FDA clearance for blood cancer diagnostics

Beckman Coulter has obtained clearance under the FDA's de novo pathway to market its ClearLLab Reagents. The tests facilitate the diagnosis of non-Hodgkin lymphoma, chronic and acute leukemia, myeloma and other rare blood cancers using flow cytometry.

Full Story: